Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
The Dow Jones opened up by 1.01%, the Nasdaq rose by 1.67%, and the S&P 500 increased by 1.02%. Leading tech stocks saw Microsoft rise 12.13%, AMD up 7.09%, while Meta Platforms fell 10.18%. The Nasdaq Golden Dragon China Index gained 0.99%, with XPeng Group down 2.14% and Pinduoduo down 2.02%.

The Dow Jones opened up by 1.01%, the Nasdaq rose by 1.67%, and the S&P 500 increased by 1.02%. Leading tech stocks saw Microsoft rise 12.13%, AMD up 7.09%, while Meta Platforms fell 10.18%. The Nasdaq Golden Dragon China Index gained 0.99%, with XPeng Group down 2.14% and Pinduoduo down 2.02%.

智通财经智通财经2026/07/31 06:38
Show original
The Dow Jones opened up 1.01%, Nasdaq rose 1.67%, and S&P 500 increased 1.02%. Leading tech stocks: Microsoft surged 12.13%, Super Micro Computer rose 7.09%, Meta Platforms fell 10.18%. The Nasdaq Golden Dragon China Index climbed 0.99%, XPeng Group dropped 2.14%, and Pinduoduo declined 2.02%.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds